A detailed history of China Universal Asset Management Co., Ltd. transactions in Royalty Pharma PLC stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 85,879 shares of RPRX stock, worth $2.23 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
85,879
Previous 85,879 -0.0%
Holding current value
$2.23 Million
Previous $2.61 Million -0.0%
% of portfolio
0.34%
Previous 0.33%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$27.46 - $31.33 $939,324 - $1.07 Million
34,207 Added 66.2%
85,879 $2.61 Million
Q4 2023

May 21, 2024

SELL
$26.21 - $29.22 $896,565 - $999,528
-34,207 Reduced 39.83%
51,672 $1.45 Million
Q4 2023

Jan 23, 2024

BUY
$26.21 - $29.22 $1.05 Million - $1.17 Million
40,149 Added 348.42%
51,672 $1.45 Million
Q3 2023

May 21, 2024

BUY
$26.26 - $31.38 $148,342 - $177,265
5,649 Added 96.17%
11,523 $312,000
Q3 2023

Oct 30, 2023

BUY
$26.26 - $31.38 $148,342 - $177,265
5,649 Added 96.17%
11,523 $313,000
Q2 2023

May 21, 2024

SELL
$29.6 - $36.56 $3,877 - $4,789
-131 Reduced 2.18%
5,874 $180,000
Q2 2023

Jul 27, 2023

SELL
$29.6 - $36.56 $3,877 - $4,789
-131 Reduced 2.18%
5,874 $181,000
Q1 2023

May 21, 2024

BUY
$32.77 - $39.4 $49,941 - $60,045
1,524 Added 34.01%
6,005 $216,000
Q1 2023

Apr 27, 2023

BUY
$32.77 - $39.4 $49,941 - $60,045
1,524 Added 34.01%
6,005 $216,000
Q4 2022

May 21, 2024

SELL
$39.17 - $44.04 $3.19 Million - $3.58 Million
-81,398 Reduced 94.78%
4,481 $177,000
Q4 2022

Jan 31, 2023

BUY
$39.17 - $44.04 $15,197 - $17,087
388 Added 9.48%
4,481 $177,000
Q3 2022

Oct 21, 2022

BUY
$39.88 - $44.65 $163,228 - $182,752
4,093 New
4,093 $164,000

Others Institutions Holding RPRX

About Royalty Pharma plc


  • Ticker RPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 437,139,008
  • Market Cap $11.3B
  • Description
  • Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...
More about RPRX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.